Clinical Trials Browser

Adenocarcinoma Of Esophagus × Irinotecan × 90 days × Clear all

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06356311 2026-02-27

TroFuse-015

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms